Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer

Epigenomics

Volumn 5, Issue 6, 2013, Pages 595-598

  Stone, Andrew ^a   Valdes Mora, Fatima ^a,b   Clark, Susan J ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

biomarker; breast cancer; DNA methylation; endocrine resistance

Indexed keywords

GENOMIC DNA; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; COLORECTAL CANCER; CPG ISLAND; DISTANT METASTASIS; DNA METHYLATION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BCL-2; HUMANS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84889645659     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.70     Document Type: Review

References (31)

1. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17(5), 1474-1481 (1999
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9(9), 631-643 (2009
3. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J. Clin. Oncol. 29(17), 2301-2304 (2011
4. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005
5. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28(20), 3271-3277 (2010
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007
7. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 94(8), 1087-1092 (2006
8. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: The time is now. Crit. Rev. Oncol. Hematol. 68(1), 1-11 (2008
9. How Kit A, Nielsen HM, Tost J. DNA methylation based biomarkers: Practical considerations and applications. Biochimie 94(11), 2314-2337 (2012
10. Nogueira Da Costa A, Herceg Z. Detection of cancer-specific epigenomic changes in biofluids: Powerful tools in biomarker discovery and application. Mol. Oncol. 6(6), 704-715 (2012
11. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659-1665 (2001
12. Van De Voorde L, Speeckaert R, Van Gestel D et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat. Res. 751(2), 304-325 (2012
13. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. Am. J. Pharmacogenomics 5(4), 223-232 (2005
14. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005
15. Agrelo R, Cheng WH, Setien F et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23), 8822-8827 (2006
16. Veeck J, Ropero S, Setien F et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28(29), e563-e564; author reply e565-e566 (2010
17. Stone A, Cowley MJ, Valdes-Mora F et al. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol. Cancer Ther. 12(9), 1874-1885 (2013
18. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C. A multimarker model to predict outcome in tamoxifen-Treated breast cancer patients. Clin. Cancer Res. 12(4), 1175-1183 (2006
19. Babidge WJ, Butler LM, Burton MA, Cowled PA. Methylation of CpG sites in exon 2 of the bcl-2 gene occurs in colorectal carcinoma. Anticancer Res. 21(4A), 2809-2814 (2001
20. Dauksa A, Gulbinas A, Barauskas G, Pundzius J, Oldenburg J, El-Maarri O. Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: A pilot study. PLoS ONE 7(5), e37509 (2012
21. Scher MB, Elbaum MB, Mogilevkin Y et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J. Urol. 188(6), 2101-2107 (2012
22. Stone A, Valdes-Mora F, Gee JM et al. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS ONE 7(7), e40466 (2012
23. Magnani L, Stoeck A, Zhang X et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl Acad. Sci. USA 110(16), e1490-e1499 (2013
24. Bertelli G, Paridaens R. Optimal sequence of hormonotherapy in advanced breast cancer. Curr. Opin. Oncol. 18(6), 572-577 (2006
25. Fan M, Yan PS, Hartman-Frey C et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66(24), 11954-11966 (2006
26. Hinshelwood RA, Melki JR, Huschtscha LI et al. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum. Mol. Genet. 18(16), 3098-3109 (2009
27. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62(14), 3925-3928 (2002
28. Wong EM, Southey MC, Fox SB et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-Associated pathology in early-onset breast cancer. Cancer Prev. Res. 4(1), 23-33 (2011
29. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium methylation 450K technology. Epigenomics 3(6), 771-784 (2011
30. Bock C, Tomazou EM, Brinkman AB et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotech. 28(10), 1106-1114 (2010
31. TCGA Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61-70 (2012